To advance our mission of addressing serious unmet medical needs, we have built a portfolio of compounds that is impressive in both quality and breadth. We began 2008 with 15 products in Phase II clinical trials and beyond. The company's pipeline has grown as we have taken a balanced approach to development, supporting internal research and development programs as well as actively seeking opportunities outside of Biogen Idec through a disciplined business-development strategy.
Looking forward, Biogen Idec is making important advances in its late-stage clinical pipeline, accruing patients to registrational programs for three novel molecules: galiximab, an anti-CD80 monoclonal antibody for non-Hodgkin's lymphoma; lumiliximab, an anti-CD23 monoclonal antibody for chronic lymphocytic leukemia (CLL); and BG-12, an oral fumarate for relapsing-remitting MS. Additionally, RITUXAN is in late-stage clinical trials for CLL, MS and lupus.
The company has also initiated a Phase III clinical trial of lixivaptan in hyponatremia, a condition associated with acute heart failure, and expects to initiate a registrational program for ADENTRI in acute decompensated congestive heart failure. Biogen Idec anticipates having, on average, four times as many patients in clinical trials in 2008 as compared to 2007.
In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale. Biogen Idec is one of a handful of biotechnology companies that has two licensed and dedicated biological bulk-manufacturing facilities, including its large-scale manufacturing plant in Research Triangle Park, NC, which is one of the world's largest cell culture facilities. Biogen Idec is also building an international large-scale manufacturing facility in Hillerød, Denmark, which is scheduled to be complete in 2009. At that time, Biogen Idec will have nearly 200,000 liters of capacity for the manufacture of biologics."